The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity observed in a phase I dose escalation trial of the hypoxia-activated, NO prodrug, RRx001.
Tony R. Reid
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Curtis Scribner
No relevant relationships to disclose
Susan Jane Knox
No relevant relationships to disclose
Bryan Oronsky
No relevant relationships to disclose
Janet L. Stephens
No relevant relationships to disclose
Jan Scicinski
No relevant relationships to disclose